Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 16,135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorder Clear all

Conditions: Rheumatoid Arthritis
Interventions: Dental Plaque, Multi-dimensional health assessment questionnaire (MDHAQ), Saliva Collection; Procedure · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Gainesville, Florida

Conditions: Juvenile Idiopathic Arthritis
Interventions: Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 9
States / cities: Little Rock, Arkansas • Chicago, Illinois • Hackensack, New Jersey + 6 more

Conditions: Urothelial Carcinoma, Melanoma, Cervical Carcinoma in Situ
Interventions: SAbR Treatment of Lesions; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hyperthermia
Interventions: Control, Fan, Fan and Water Spray, Water Spray; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Psoriasis, Metabolic Syndrome
Interventions: Not listed
Lead sponsor: Tufts Medical Center; Other
Eligibility: 10 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Side-effect questionnaires, research blood samples; Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 13
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 9 more

Conditions: Prostatic Neoplasm, Survivorship, Frailty, Aging, Metastatic Breast Cancer
Interventions: Dietary recommendations, Time-restricted eating; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 55 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer, Gastric Cancer, Hepatecellular Carcinoma, NSCLC (Advanced Non-small Cell Lung Cancer), Mesothelioma, Pancreatic Carcinoma Metastatic, Hormone Refractory Prostate Cancer, Soft Tissue Sarcomas
Interventions: SHY-ONC6; Drug
Lead sponsor: SHY Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Scottsdale, Arizona • Houston, Texas • San Antonio, Texas

Conditions: Erythematotelangiectatic Rosacea
Interventions: CD07805/47, CD07805/47 placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 5
States / cities: Hot Springs, Arkansas • Fort Washington, Pennsylvania • Austin, Texas + 2 more

Conditions: Breast Cancer
Interventions: doxorubicin hydrochloride, enalapril maleate; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Edina, Minnesota • Minneapolis, Minnesota

Conditions: Breast Cancer
Interventions: Erlotinib with neoadjuvant chemotherapy; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
Interventions: Imvotamab, Placebo; Drug
Lead sponsor: IGM Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Flagstaff, Arizona • Glendale, Arizona • San Diego, California + 7 more

Conditions: Infections, Gram-Positive Bacterial, Abscess, Burns, Cellulitis, Ulcer, Wound Infections
Interventions: Telavancin, Vancomycin or antistaphylococcal penicillin; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Cancers With HER2 Expression
Interventions: BAY2701439; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more

Conditions: Cancer
Interventions: captopril, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Unresectable Stage III, Stage IV Melanoma
Interventions: Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 79
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 76 more

Conditions: Wound; Head, Multiple, Wound; Head, Scalp, Wound; Head, Wound Infection, Wound Complication, Wound Dehiscence, Wound of Skin, Wound Open, Wounds, Penetrating, Wounds, Nonpenetrating, Wounds and Injuries, Wounds, Disturbance of Wound Healing, Facial Bones Fracture, Soft Tissue Injuries, Skull Fractures, Surgical Wound, Surgical Wound Infection, Wound Healing
Interventions: Not listed
Lead sponsor: Dufresne, Craig, MD, PC; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Breast Cancer, Solid Tumor, Adult
Interventions: APG-2575, Palbociclib; Drug
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Atlanta, Georgia • Austin, Texas • Houston, Texas + 1 more

Conditions: Rheumatoid Arthritis
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Pasadena, Texas

Conditions: Lipodystrophy, Diabetes, Hyperlipidemia
Interventions: Metreleptin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Months to 98 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Polyarticular Juvenile Rheumatoid Arthritis, Arthritis, Juvenile Idiopathic
Interventions: Not listed
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 2 Years to 18 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 52
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 41 more

Conditions: Melanoma
Interventions: TLPLDC, Placebo; Drug
Lead sponsor: Elios Therapeutics, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 15 more

Conditions: Dermatitis, Atopic
Interventions: PF-04965842 100 mg, PF-04965842 200 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 28
States / cities: Anaheim, California • Los Alamitos, California • Rolling Hills Estates, California + 20 more

Conditions: Infections, Herpesviridae
Interventions: Valaciclovir, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 17
States / cities: Carmichael, California • Davis, California • Riverside, California + 13 more

Search by objective public record fields.

Oral Metagenomic Biomarkers in Rheumatoid Arthritis

Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis

SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma

Skin Surface and Intradermal Temperature Responses to Heat Stress

Peds Metabolic Syndrome in Psoriasis

Investigation of Genetic Determinants of Capecitabine Toxicity

Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea

Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer

Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis

Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation

An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds

A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis

Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy

Start Time Optimization of Biologics in Polyarticular JIA

Phase IIB TL + YCWP + DC in Melanoma

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.